Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates

被引:107
作者
Cheng, AFB
Yew, WW
Chan, EWC
Chin, ML
Hui, MMM
Chan, RCY
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Microbiol, Shatin, Hong Kong, Peoples R China
[2] Grantham Hosp, TB & Chest Unit, Aberdeen, Hong Kong, Peoples R China
关键词
D O I
10.1128/AAC.48.2.596-601.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A new strategy known as multiplex PCR amplimer conformation was developed for detection of mutation in the gyrA gene of 138 clinical isolates of Mycobacterium tuberculosis. The method generated a single-stranded and heteroduplex DNA banding pattern of multiplex PCR amplimers of the region of interest that was extremely sensitive to specific mutations, thus enabling much more sensitive and reliable mutation analysis compared to the standard single-stranded conformation polymorphism technique. The genetic profiles of the gyrA gene of the 138 isolates as detected by MPAC were confirmed by nucleotide sequencing and were found to correlate strongly with the in vitro susceptibilities of the mutant strains to six fluoroquinolones (oftoxacin, levofloxacin, sparfloxacin, moxifloxacin, gatifloxacin, and sitafloxacin). All 32 isolates that contained gyrA mutations exhibited cross-resistance to the six fluoroquinolones (ofloxacin MIC for 90% of strains > 16 mg/liter), although moxifloxacin, gatifloxacin, and sitafloxacin (MIC for 90% of strains greater than or equal to 4 mg/liter) were apparently more active than ofloxacin, levofloxacin, and sparfloxacin (MIC for 90% of strains less than or equal to 16 mg/liter). All gyrA mutations were clustered in codons 90, 91, and 94, and aspartic acid 94 was most frequently mutated. Twenty-three isolates without gyrA mutations were also found to exhibit reduced susceptibility to oftoxacin (MIC for 90% of strains = 4 mg/liter), but largely remained susceptible to other drugs (MIC for 90% of strains less than or equal to 1 mg/liter). Another 83 isolates without mutations were fully susceptible to all six fluoroquinolones (ofloxacin MIC for 90% of strains = 1 mg/liter). In conclusion, high-level phenotypic resistance to fluoroquinolones among M. tuberculosis clinical isolates, which appears to be predominantly due to gyrA mutations, may be readily detected by genotyping techniques such as multiplex PCR amplimer conformation.
引用
收藏
页码:596 / 601
页数:6
相关论文
共 35 条
[1]   CHARACTERIZATION OF FLUOROQUINOLONE-RESISTANT MUTANT STRAINS OF MYCOBACTERIUM-TUBERCULOSIS SELECTED IN THE LABORATORY AND ISOLATED FROM PATIENTS [J].
ALANGADEN, GJ ;
MANAVATHU, EK ;
VAKULENKO, SB ;
ZVONOK, NM ;
LERNER, SA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (08) :1700-1703
[2]  
CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21
[3]   Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus [J].
Dong, YZ ;
Zhao, XL ;
Domagala, J ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) :1756-1758
[4]   Fluoroquinolone action against mycobacteria: Effects of C-8 substituents on growth, survival, and resistance [J].
Dong, YZ ;
Xu, C ;
Zhao, XL ;
Domagala, J ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) :2978-2984
[5]   Mutant prevention concentration as a measure of antibiotic potency:: Studies with clinical isolates of Mycobacterium tuberculosis [J].
Dong, YZ ;
Zhao, XL ;
Kreiswirth, BN ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2581-2584
[6]   Activity of 16 antimicrobial agents against drug-resistant strains of Mycobacterium tuberculosis [J].
Fattorini, L ;
Iona, E ;
Ricci, ML ;
Thoresen, OF ;
Orrù, G ;
Oggioni, MR ;
Tortoli, E ;
Piersimoni, C ;
Chiaradonna, P ;
Tronci, M ;
Pozzi, G ;
Orefici, G .
MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE, 1999, 5 (04) :265-270
[7]   In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin [J].
Fung-Tomc, J ;
Minassian, B ;
Kolek, B ;
Washo, T ;
Huczko, E ;
Bonner, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (04) :437-446
[8]   Activity of moxifloxacin against mycobacteria [J].
Gillespie, SH ;
Billington, O .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (03) :393-395
[9]  
Grimaldo ER, 2001, INT J TUBERC LUNG D, V5, P546
[10]   Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria [J].
Guillemin, I ;
Jarlier, V ;
Cambau, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :2084-2088